Trueblue (TBI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
9 Jan, 2026Executive summary
Announced response to EHS Management's intent to nominate director candidates for the 2026 annual meeting.
Highlighted ongoing strategic initiatives focused on profitable growth, digital transformation, and operational efficiency.
Emphasized recent board refreshment and appointments aligned with long-term strategy.
Asserted no shareholder action is required at this time; recommendations will be provided in the definitive proxy statement.
Forward-looking statements address expectations for market recovery, digital investment growth, and risk factors.
Voting matters and shareholder proposals
EHS Management disclosed intent to nominate director candidates at the 2026 annual meeting.
Shareholders are advised to await the company's definitive proxy statement for voting recommendations.
The company will file a proxy statement and BLUE proxy card for the 2026 meeting.
Board of directors and corporate governance
Board composition evolved to align with strategic priorities, enhance diversity, and strengthen oversight.
Two new directors, William Greenblatt and William Seward, appointed for their industry and operational expertise.
Two current directors will retire at or before the 2026 annual meeting.
Board engaged with shareholders and EHS Management during the refreshment process.
Board determined new appointees better fit strategic needs than EHS's nominee.
Latest events from Trueblue
- Board refreshment and profitability initiatives advance as proxy contest with EHS continues.TBI
Proxy Filing3 Mar 2026 - Revenue up 8% to $418M, but net loss widened on impairment; margin pressure persists.TBI
Q4 202518 Feb 2026 - Q2 revenue down 17% to $396M, net loss $105M, with cost cuts and digital focus amid uncertainty.TBI
Q2 20242 Feb 2026 - Digital innovation and market expansion drive growth and margin gains in a fragmented staffing sector.TBI
Sidoti September Small-Cap Virtual Conference20 Jan 2026 - Q3 revenue dropped 19.2% with a $59.1M goodwill impairment and strong cost controls.TBI
Q3 202416 Jan 2026 - Board refreshment and strategic focus highlighted as proxy process begins for 2026.TBI
Proxy Filing9 Jan 2026 - Q4 revenue fell 22% but margin gains, cost cuts, and healthcare expansion support recovery.TBI
Q4 202424 Dec 2025 - Board appointments and refreshment aim to drive growth, oversight, and long-term value.TBI
Proxy Filing2 Dec 2025 - Shareholders will vote on directors, executive pay, incentive plan, and auditor, with strong governance and ESG focus.TBI
Proxy Filing1 Dec 2025